AAP Grand Rounds Subscribe to Pediatrics in Review
HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Take the CME quiz:
 Vol. 19 No. 6, June 2008
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Varma, S. K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Varma, S. K.

AAP Grand Rounds 19:69-70 (2008)
© 2008 American Academy of Pediatrics

ENDOCRINOLOGY

Safety of Growth Hormone for Children with Turner Syndrome

Source: Bolar K, Hoffman AR, Maneatis T, et al. Long-term safety of recombinant human growth hormone in Turner syndrome. J Clin Endocrinol Metab. 2008;93(2):344–351; doi:10.1210/ jc.2007-1723.[Abstract/Free Full Text]

The first 20% of the full text of this article appears below.


PICO

Question: What is the safety profile for human growth hormone in children with Turner syndrome?

Question type: Harm

Study design: Prospective cohort of post-marketing surveillance

 

To assess the safety of treating children with Turner Syndrome (TS) with recombinant human growth hormone (rhGH), researchers from the University of Texas-Galveston, Stanford, and Genentech, Inc. reviewed data collected as part of the National Cooperative Growth Study (NCGS). The NCGS is an ongoing project of Genentech. Investigators beginning patients on a Genentech rhGH product are required to provide reports of serious adverse events (AEs) and targeted AEs, irrespective of relationship to rhGH, including malignancy, diabetes mellitus, intracranial hypertension (IH), scoliosis, slipped femoral epiphysis (SCFE), and pancreatitis.

For the current study, safety data for 5,220 children with TS and almost 50,000 non-TS patients treated with . . . [Full Text of this Article]

Surendra K. Varma, MD, FAAP
Texas Tech University Health Sciences Center, Lubbock, TX

 





HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Academy of Pediatrics.